Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Two US Biopharmas -- Stealth and AOBiome -- File for IPOs on Hong Kong Exchange

publication date: Jul 5, 2018

Two young Boston-area biotechs have filed with the Hong Kong Exchange to conduct IPOs on the exchange, taking advantage of the new rules allowing pre-revenue companies to list and seeking the high valuations Hong Kong investors offer. Stealth BioTherapeutics and AOBiome Therapeutics are both developing novel drugs that are in (or close to) Phase III trials. The two US biopharmas join two China companies -- Ascletis and Innovent -- that have already filed for Hong Kong IPOs, while more are expected to follow soon. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital